Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH versus XERAVA.
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade produces bactericidal effect.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Sulfamethoxazole: 9-11 hours; trimethoprim: 8-11 hours. In severe renal impairment (CrCl <15 mL/min), half-life prolongs significantly (up to 30 hours for trimethoprim).
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Both sulfamethoxazole and trimethoprim are primarily excreted via the kidneys. Sulfamethoxazole: ~30% as unchanged drug, ~50% as N4-acetyl metabolite; trimethoprim: ~80% as unchanged drug. Fecal elimination is minimal (<5%).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category D/X
Category C
Antibiotic
Antibiotic